CervoMed Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
20 PARK PLAZA, BOSTON, MA, 02116
Mailing Address
20 PARK PLAZA, BOSTON, MA, 02116
Phone
(617) 744-4400
Fiscal Year End
1231
EIN
300645032
Financial Overview
FY2025
$39.20M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 8-K Current report of material events | March 17, 2026 | View on SEC |
| 10-K Annual financial report | March 13, 2026 | View on SEC |
| 8-K Current report of material events | March 4, 2026 | View on SEC |
| 8-K Current report of material events | February 18, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
Annual Reports
10-K
March 13, 2026
- Positive 16-week results from the RewinD-LB Trial Extension for neflamapimod in DLB patients.
- Successfully secured approximately $149.4 million through a private placement in April 2024, extending cash runway.
Material Events
8-K
Other
March 19, 2026
High Impact
- Neflamapimod showed significantly improved efficacy in a specific dementia with Lewy bodies (DLB) patient group (low pTau181) from re-analyzed Phase 2b data.
- This discovery provides a clear, de-risked path for future drug development, allowing for targeted Phase 3 trials with higher success rates.
8-K
Financial Distress
March 17, 2026
High Impact
- Positive Phase 2b RewinD-LB trial results for neflamapimod in Dementia with Lewy Bodies (DLB), showing significant and clinically meaningful effects.
- FDA and global regulators have approved the design for the upcoming Phase 3 trial for neflamapimod in DLB.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.